FDA puts on hold two drug trials of Rapt Therapeutics in 'major setback'

The U.S. FDA placed a hold on Rapt Therapeutics' two mid-stage trials for eczema and asthma treatment after a patient experienced liver failure. The patient had a drug allergy, and Hashimoto's disease, used a herbal supplement, and had a COVID-19 infection. Analysts anticipate significant trial delays. Rapt will halt dosing and enrollment for investigation, affecting about 350 patients across trials. No prior evidence of liver toxicity was reported in other patients.